Shares of UnitedHealth Group surged 7% to $447.67 this morning after the nation's largest health insurer reported a second-quarter 2026 earnings beat and raised its full-year adjusted earnings-per-share guidance to $19.50–$20.00 — a dramatic leap from the >$18.25 target set just last quarter. The move adds roughly $26 billion in market value in a single session, but the real question is whether profitability gains can keep outrunning a shrinking customer base.
• The Profit Machine Is Running Ahead of Schedule. In Q1, UnitedHealth beat adjusted EPS consensus by roughly 10%, reporting $7.23 versus expectations of $6.59–$6.76, and raised full-year guidance by $0.50. Now, lifting the target again to $19.50–$20.00 means management has boosted its profit outlook by more than $2.00/share since January, when it originally guided for adjusted earnings greater than $17.75. That kind of successive upward revision signals real operating momentum, not just accounting noise.
• Better Margins Are Doing the Heavy Lifting, Not Revenue Growth. UnitedHealth's medical cost ratio — the share of premiums spent on patient care — fell to 83.9% in Q1, down 90 basis points year-over-year. That improvement, driven by premium repricing catching up to inflation in medical costs, is translating directly into fatter profits even as Q2 revenue was expected to edge down roughly 0.8% year-over-year to about $110.8 billion. Investors are rewarding margin discipline over top-line growth — for now.
• The Membership Decline Remains the Elephant in the Room. Medicare Advantage enrollment is projected at 7.43 million, down from 8.35 million a year ago.
Risk-based commercial membership is forecast to drop to 7.26 million from 8.44 million. UnitedHealth is deliberately shedding unprofitable members to improve margins — a strategy that works until pricing power plateaus and there are fewer lives left to squeeze.
• Wall Street Was Already Stretched Before Today's Pop. The average analyst price target before today was $413.16 , and at $447.67, UNH now trades above most targets. Truist's David Macdonald carried one of the Street's highest targets at $480 , suggesting limited upside unless estimates reset sharply higher. At roughly 23x the new $19.75 midpoint guidance, investors are paying a premium that assumes this margin recovery extends through 2027 and beyond — a bet that leaves little room for disappointment.